Company News
Company News
CORE ONE LABS’ CLINICS SUBMIT APPLICATION TO TREAT PATIENT WITH PSILOCYBIN PSYCHEDELIC- ASSISTED THERAPY
August 12, 2021
Vancouver, British Columbia, Canada – August 13, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused...
Read more
Company News
Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development
August 07, 2021
Vancouver, British Columbia, Canada – August 7, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”)...
Read more
Company News
Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion
August 04, 2021
Vancouver, British Columbia, Canada – August 4, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”)...
Read more
Company News
CORE ONE’S DR. ROBERT E.W. HANCOCK TO HOST VIRTUAL TOWNHALL WEBCAST AND PRESENT ON PROPRIETARY BIOSYNTHESIZED PSILOCYBIN WEDNESDAY, AUGUST 4, 2021
July 30, 2021
Vancouver, British Columbia, Canada – July 30, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”)...
Read more
Company News
CORE ONE LABS’ AKOME SEEKS TO REVOLUTIONIZE TREATMENT OF PARKINSON’S DISEASE AND SUBMITS APPLICATION TO PROTECT IP
July 26, 2021
Vancouver, British Columbia, Canada – July 26, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce...
Read more
Company News
CORE ONE LABS’ AKOME BIOTECH PROTECTS NEW AK0003 KETAMINE-BASED BREAKTHROUGH DRUG FORMULATION FOR DEPRESSION TREATMENT
July 21, 2021
Vancouver, British Columbia, Canada – July 21, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce...
Read more